Literature DB >> 831755

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

R Peto, M C Pike, P Armitage, N E Breslow, D R Cox, S V Howard, N Mantel, K McPherson, J Peto, P G Smith.   

Abstract

Part I of this report appeared in the previous issue (Br. J. Cancer (1976) 34,585), and discussed the design of randomized clinical trials. Part II now describes efficient methods of analysis of randomized clinical trials in which we wish to compare the duration of survival (or the time until some other untoward event first occurs) among different groups of patients. It is intended to enable physicians without statistical training either to analyse such data themselves using life tables, the logrank test and retrospective stratification, or, when such analyses are presented, to appreciate them more critically, but the discussion may also be of interest to statisticians who have not yet specialized in clinical trial analyses.

Entities:  

Mesh:

Year:  1977        PMID: 831755      PMCID: PMC2025310          DOI: 10.1038/bjc.1977.1

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  5 in total

1.  BCG in the treatment of acute lymphocytic leukemia.

Authors:  R M Heyn; P Joo; M Karon; M Nesbit; N Shore; N Breslow; J Weiner; A Reed; D Hammond
Journal:  Blood       Date:  1975-09       Impact factor: 22.113

Review 2.  Statistical methods for the identification and use of prognostic factors.

Authors:  P Armitage; E A Gehan
Journal:  Int J Cancer       Date:  1974-01-15       Impact factor: 7.396

3.  Active immunotherapy for acute lymphoblastic leukaemia.

Authors:  G Mathé; J L Amiel; L Schwarzenberg; M Schneider; A Cattan; J R Schlumberger; M Hayat; F De Vassal
Journal:  Lancet       Date:  1969-04-05       Impact factor: 79.321

4.  Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data.

Authors:  R Peto; M C Pike
Journal:  Biometrics       Date:  1973-09       Impact factor: 2.571

5.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03
  5 in total
  1232 in total

Review 1.  Randomised controlled trials in cardiovascular medicine: past achievements, future challenges.

Authors:  S Yusuf
Journal:  BMJ       Date:  1999-08-28

2.  Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial.

Authors:  G Pomier-Layrargues; J P Villeneuve; M Deschênes; B Bui; P Perreault; D Fenyves; B Willems; D Marleau; M Bilodeau; M Lafortune; M P Dufresne
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

3.  Erythroleukaemia in the north of England: a population based study.

Authors:  A W Wells; N Bown; M M Reid; P J Hamilton; G H Jackson; P R Taylor
Journal:  J Clin Pathol       Date:  2001-08       Impact factor: 3.411

4.  Glossary on meta-analysis.

Authors:  M Delgado-Rodríguez
Journal:  J Epidemiol Community Health       Date:  2001-08       Impact factor: 3.710

Review 5.  Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic?

Authors:  N Freemantle
Journal:  BMJ       Date:  2001-04-21

6.  Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

Authors:  Jeffrey E Rubnitz; Hiroto Inaba; Gary Dahl; Raul C Ribeiro; W Paul Bowman; Jeffrey Taub; Stanley Pounds; Bassem I Razzouk; Norman J Lacayo; Xueyuan Cao; Soheil Meshinchi; Barbara Degar; Gladstone Airewele; Susana C Raimondi; Mihaela Onciu; Elaine Coustan-Smith; James R Downing; Wing Leung; Ching-Hon Pui; Dario Campana
Journal:  Lancet Oncol       Date:  2010-05-05       Impact factor: 41.316

7.  Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

Authors:  Marco Colleoni; Bernard F Cole; Giuseppe Viale; Meredith M Regan; Karen N Price; Eugenio Maiorano; Mauro G Mastropasqua; Diana Crivellari; Richard D Gelber; Aron Goldhirsch; Alan S Coates; Barry A Gusterson
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

8.  Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis.

Authors:  A Gramenzi; P Andreone; S Fiorino; C Cammà; M Giunta; D Magalotti; C Cursaro; C Calabrese; V Arienti; C Rossi; G Di Febo; M Zoli; A Craxì; G Gasbarrini; M Bernardi
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

9.  The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group.

Authors:  R Sposto; I J Ertel; R D Jenkin; C P Boesel; J L Venes; J A Ortega; A E Evans; W Wara; D Hammond
Journal:  J Neurooncol       Date:  1989-07       Impact factor: 4.130

10.  Mucin 2 (MUC2) and mucin 5 (MUC5) expression is not associated with prognosis in patients with radically resected ampullary carcinoma.

Authors:  D Santini; A Baldi; B Vincenzi; P Mellone; M Campioni; A Antinori; D Borzomati; R Coppola; P Magistrelli; G Tonini
Journal:  J Clin Pathol       Date:  2007-09       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.